The new patent is a continuation-in-part of the company’s core patent which applies to the use of magnetic nanoparticles for the detection of diseases such as cancer.
“This is an important addition to our intellectual property portfolio,” said Bob Proulx, Executive Chairman. “We have long held the view that using our targeted magnetic nanoparticles for detection cancer was only the first step. There is a much broader opportunity to combine detection with treatment.”
View the entire announcement here.
This news was lodged with the Australian Securities Exchange.